We are welcoming submissions to our new collection on molecular mimicry in human diseases, guested edited by Luigi Buonaguro and Jamie Rossjohn.
Submission Deadline: 15 December 2024
Submit to our new collection, "Planeterranean" Diet: Globally Extending the Health Benefits of the Mediterranean Diet, guest edited by Luigi Barrea, Salvatore Nesci, Prisco Piscitelli, Laura Soldati, and Claudia Vetrani.
Submission Deadline: 30 June 2024
Get to know the Editors behind Journal of Translational Medicine!
The Neuroscience section aims to encourage publications that help to reduce the gap between basic preclinical science and medical applications for the patients in the neuroscience field. Any new tool for the dissemination of results in the field can greatly help to progress in the new solutions for the neuropsychiatric patient. The section aims to promote the increase of knowledge on the subject by publishing original research.
JAK-STAT signalling pathway inhibitors have emerged as promising therapeutic agents for the treatment of hair loss. Among different JAK isoforms, JAK3 has become an ideal target for drug discovery because it only regulates a narrow spectrum of γc cytokines. Here, we report the discovery of MJ04, a novel and highly selective 3-pyrimidinylazaindole based JAK3 inhibitor, as a potential hair growth promoter with an IC50 of 2.03 nM. During in vivo efficacy assays, topical application of MJ04 on DHT-challenged AGA and athymic nude mice resulted in early onset of hair regrowth. We report MJ04 as a highly potent and selective JAK3 inhibitor that exhibits overall properties suitable for topical drug development and advancement to human clinical trials.
The shortage of organs for transplantation emphasizes the urgent need for alternative solutions. Xenotransplantation has emerged as a promising option due to the greater availability of donor organs. To address the challenges of immune rejection, gene-edited pigs have become a focal point, aiming to shield donor organs from human immune responses and enhance the overall success of xenotransplantation. This comprehensive review aims to illuminate strategies for regulating complement networks to optimize the efficacy of gene-edited pig xenotransplantation. These investigations provide valuable insights into the feasibility and potential success of xenotransplantation, offering a bridge between scientific advancements and clinical application.
Journal of Translational Medicine has launched In Review, a new option that provides authors with on-demand information on the status of their manuscript, enables them to share their work with funders and their research community, and allows their colleagues to comment and collaborate - all whilst their manuscript is under review.
Read MoreEdited by Dr Mary Salvatore &
Dr Monica Pernia
Check out the most discussed articles from the previous month!
Translational Medicine Communications. the companion journal to Journal of Translational Medicine, is an interdisciplinary forum for all scientifically valid research from across translational medicine.
The journal aims to improve transparency and reproducibility within translational medicine and considers research papers regardless of outcome or significance of findings.
Led by Section Editor Sarah Warren, the Molecular Pathology section aims to highlight studies that characterize human-derived biological materials, including both tissue and liquid biopsies, using molecular profiling techniques to elucidate the underlying causes of disease and impacts of therapeutic interventions.
The Molecular Pathology section will consider studies that are preclinical or translational in nature, as well as from all stages of fundamental and applied research. The section welcomes manuscripts that describe new technology platforms that advance molecular profiling or novel computational approaches to support data analysis.
Led by Section Editor Joyce Hu, the Network Medicines section is dedicated to the biology-based, integrative approach aimed at understanding the topology of complex disorders and the dynamic interplay of their various components, identifying cascades of causes and effects, listening to cross-talks among cells to suggest novel and more effective therapeutic approaches.
The section welcomes research that goes beyond descriptive observations and provides compelling recommendations of disruptive therapeutic candidates.
Led by Marina Boccardi, the Translational Process section welcomes contributions aimed to streamline the transition of new knowledge along the translational continuum, and boost our ability to concretely innovate clinical practice.
The Translational Process section dedicates a space to those who tackle such challenges overcoming the boundaries of individual disciplines, and offers a new opportunity to share and accelerate the development of urgently needed methods, tools and procedures.
Led by Section Editor Matteo Alessandro Avella, the Reproductive Medicine & Clinical Reproductive Science section is focused on the basic mechanisms or the translational and clinical aspects of human reproductive biology.
The section welcomes studies on preclinical and clinical studies whose results have the potential to prevent, diagnose, and treat reproductive issues, as well as studies that describe and characterize the genes and the mechanisms regulating human reproductive biology in cell line or animal models, and reviews on existing and novel technologies.
Franco Marincola is the Chief Scientific Officer of Sonata Therapeutics. Franco brings over 30 years of research and development experience in immunology, oncology and cell therapy to Sonata.
Most recently, Franco served as Senior Vice President and Global Head of Research at Kite Pharma where he led the research organization to identify novel therapies for hematologic malignancies and solid tumors. Prior to Kite, he was President and Chief Scientific Officer at Refuge Biotechnologies, where he developed research strategies for adoptive cell therapy products and led therapeutic programs based on nuclease deactivated CRISPR circuits. Prior to Refuge, Franco was Distinguished Research Fellow in Immune Oncology at AbbVie, and Chief Research Officer at Sidra Medical and Research Centre.
Before joining the biopharma industry, Franco spent more than two decades at the National Institutes of Health (NIH) and National Cancer Institute (NCI), most recently as a tenured senior investigator in cancer immunotherapy and biomarker research and as Chief Infectious Disease and Immunogenetics Investigator at the NIH Clinical Center.
Franco is the former President of the Society for Immunotherapy of Cancer (SITC). He currently serves as Editor-in-Chief for multiple peer-reviewed publications, including Journal of Translational Medicine, Translational Medicine Communications, and Immunotherapy, and is the author of more than 600 peer-reviewed publications.
Franco received his M.D. from the University of Milan and completed his residency at Stanford University.
Journal of Translational Medicine is an open access journal publishing articles focusing on information derived from human experimentation so as to optimise the communication between basic and clinical science.
The journal covers all areas of translational medicine but also has several special sections:
|
|
|
2022 Citation Impact
7.4 - 2-year Impact Factor
6.9 - 5-year Impact Factor
1.458 - SNIP (Source Normalized Impact per Paper)
1.544 - SJR (SCImago Journal Rank)
2023 Speed
9 days submission to first editorial decision for all manuscripts (Median)
86 days submission to accept (Median)
2023 Usage
4,999,990 downloads
8,678 Altmetric mentions